Mesenchymal stem/stromal cells-derived exosomes for osteoporosis treatment

Huo, Kai-Lun; Yang, Tieyi; Zhang, Weiwei; Shao, Jianda

doi:10.4252/wjsc.v15.i3.83

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently available treatments (including anti-resorptive and anabolic drugs) control OP by promoting bone formation, impeding adipocyte development, or inhibiting OC differentiation. However, the potential adverse effects, which include fever, nausea, bone pain, and cancer, are nonnegligible ( Duan and Guan, 2021 ; Li et al, 2022 ; Huo et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic potential of mesenchymal stem cell-derived exosomes in skeletal diseases

Yang,

Zhang,

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Skeletal diseases impose a considerable burden on society. The clinical and tissue-engineering therapies applied to alleviate such diseases frequently result in complications and are inadequately effective. Research has shifted from conventional therapies based on mesenchymal stem cells (MSCs) to exosomes derived from MSCs. Exosomes are natural nanocarriers of endogenous DNA, RNA, proteins, and lipids and have a low immune clearance rate and good barrier penetration and allow targeted delivery of therapeutics. MSC-derived exosomes (MSC-exosomes) have the characteristics of both MSCs and exosomes, and so they can have both immunosuppressive and tissue-regenerative effects. Despite advances in our knowledge of MSC-exosomes, their regulatory mechanisms and functionalities are unclear. Here we review the therapeutic potential of MSC-exosomes for skeletal diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic potential of mesenchymal stem cell-derived exosomes in skeletal diseases

Yang,

Zhang,

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Laden, with an array of biologically active constituents such as lipids, proteins, DNA, and microRNA, exosomes are actively secreted into the extracellular milieu. [7][8][9] Exosomes exert their biological effects by interacting with target cells. Several studies have elucidated the varied biological functions of exosomes derived from distinct cellular sources.…”

Section: Introductionmentioning

confidence: 99%

Global scientific trends on exosomes therapy for osteoporosis from 2004 to 2023: A bibliometric and visualized analysis

Lv,

Feng,

Chen

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Exosomes have emerged as pivotal mediators in modulating physiological and pathological processes implicated in osteoporosis (OP) through their distinctive mode of intracellular communication. The use of exosomes has evoked considerable interest, catalyzing a surge in research endeavors on a global scale. This study endeavors to scrutinize contemporary landscapes and burgeoning trends in this realm. Methods: The Web of Science Core Collection was used to retrieve publications on exosomes therapy for OP within the time frame of January 1, 2004 to December 31, 2023. The bibliometric methodology was applied to study and index the collected data. VOSviewer and citespace software were used to conduct visualization, co-authorship, co-occurrence, and publication trend analyses of exosome therapy in OP. Results: A total of 610 publications (443 articles and 167 reviews) from 51 countries and 911 institutions were included in this study. Shanghai Jiao Tong University, Central South University, Sichuan University, and Zhejiang University are leading research institutions in this field. Stem Cell Research Therapy published the highest number of articles and has emerged as the most cited journal. Of the 4077 scholars who participated in the study, Xie, Hui, Zhang, Yan, Tan, and Yi-Juan had the largest number of articles. Furthermore, according to the cluster analysis of external keywords, future research hotspots can be categorized into 3 directions: research status of exosomes for the treatment of OP, treatment of OP through exosome-regulated signaling pathways, and exosomes as targeted drug delivery systems. Conclusion: This study suggests that the number of future publications on exosome therapy for OP will increase, with a focus on fundamental investigations into drug-loading capacities and molecular mechanisms. In summary, this study presents the first systematic bibliometric analysis of exosome therapy publications in OP, providing an objective and comprehensive overview of the field and a valuable reference for researchers in this domain.

show abstract

New‐QiangGuYin‐Containing Serum Inhibits Osteoclast‐Derived Exosome Secretion and Down‐Regulates Notum to Promote Osteoblast Differentiation

Meng,

Zhang,

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

New‐QiangGuYin (N‐QGY), the addition of sea buckthorn on the basis of QGY formula, is herbal formula widely used clinically in China for the treatment of osteoporosis (OP), but its mechanism warrants further exploration. The mechanisms of QGY and N‐QGY in the treatment of OP are probed from the perspective of osteoclast‐osteoblast balance. Thirty Sprague‐Dawley rats are randomly divided into N‐QGY group, QGY group, and Control group. Beyond control rats that orally took normal saline, other rats are orally administered with isometric N‐QGY or QGY twice every day for 3 days. The drug‐containing serum and control serum are prepared and their effects on osteoclast‐derived exosome secretion are determined by bicinchoninic acid assay (BCA), nanoparticle tracking analysis, and Western blot. GW4869 and Interleukin‐1β (IL‐1β) are adopted as the exosome inhibitor and inducer, respectively. Exosome uptake, cell counting kit‐8, alkaline phosphatase (ALP) staining, alizarin red staining, enzyme‐linked immunosorbent assay, quantitative real‐time polymerase chain reaction, and Western blot are performed to examine the effects of altered osteoclast exosome content on osteogenic differentiation of mesenchymal stem cells (MSCs). N‐QGY, QGY, and GW4869 inhibit osteoclast‐derived exosome secretion and exosome uptake by MSCs, whereas IL‐1β exerted the opposite effects (p < 0.05). Different from IL‐1β, N‐QGY, QGY, and GW4869 partially elevated MSC viability, osteocalcin secretion, ALP, RUNX Family Transcription Factor 2 (RUNX2) and Osteopontin (OPN) expressions, and calcium deposition in the osteoclast‐MSCs coculture system (p < 0.05). Mechanically, osteoclasts increased Notum protein level but decreased β‐catenin level, which is enhanced by IL‐1β but is reversed by GW4869, QGY, and N‐QGY (p < 0.05). And the effect of N‐QGY is more conspicuous than that of QGY (P<0.05). N‐QGY‐containing serum inhibits exosome levels in osteoclasts, thereby enhancing osteogenic differentiation of MSCs via inhibition of Notum protein and promotion of β‐catenin protein.

show abstract

Mesenchymal stem/stromal cells-derived exosomes for osteoporosis treatment

Cited by 4 publications

References 40 publications

Therapeutic potential of mesenchymal stem cell-derived exosomes in skeletal diseases

Therapeutic potential of mesenchymal stem cell-derived exosomes in skeletal diseases

Global scientific trends on exosomes therapy for osteoporosis from 2004 to 2023: A bibliometric and visualized analysis

New‐QiangGuYin‐Containing Serum Inhibits Osteoclast‐Derived Exosome Secretion and Down‐Regulates Notum to Promote Osteoblast Differentiation

Contact Info

Product

Resources

About